Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.

AIDS (London, England) - 12 Mar 2008

Poveda Eva, de Mendoza Carmen, Parkin Neil, Choe Sunny, García-Gasco Pilar, Corral Angélica, Soriano Vincent

Abstract excerpt

BACKGROUND: Tipranavir (TPV) and darunavir (DRV) are potent against protease inhibitor (PI)-resistant viruses. Efficacy of these compounds when confronting distinct HIV subtypes is not known. METHODS: All clinical specimens from HIV-positive patients sent to our institution for drug resistance testing between 1999 and 2006 were analysed. The prevalence of TPV and DRV resistance mutations was assessed based on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Genes, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to HIV Reverse Transcriptase

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Source

Identifiers

PMID: 18317002
DOI: 10.1097/QAD.0b013e3282f51eb9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.PMID 18317002Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.Semantic proximity Read ↗

HIV Genetic Diversity and Drug ResistanceSemantic proximity Read ↗

Drug resistance in non-subtype B HIV-1.Semantic proximity Read ↗

Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.Semantic proximity Read ↗

HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.Semantic proximity Read ↗

Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.Semantic proximity Read ↗

Resistance-associated mutation prevalence according to subtypes B and non-B of HIV type 1 in antiretroviral-experienced patients in Minas Gerais, Brazil.Semantic proximity Read ↗

Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.Semantic proximity Read ↗

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.Semantic proximity Read ↗

Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.Semantic proximity Read ↗

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.